Pomalidomide-6-O-CH3 is a methylated derivative of the immunomodulatory agent pomalidomide, primarily utilized in medicinal chemistry and pharmaceutical research. It is investigated for potential therapeutic applications, especially in oncology, including multiple myeloma. Studies focus on its capacity to modulate immune responses, inhibit cancer cell proliferation, and possibly exhibit altered pharmacokinetic properties due to the 6-O-methyl modification. Researchers explore its synergy with other therapeutics to improve efficacy. It is also evaluated for anti-inflammatory effects and relevance in autoimmune disorders. The compound's structure enables targeted interactions with biological pathways, positioning it as a candidate for novel drug development. Current research emphasizes optimizing its pharmacology and assessing safety for future clinical translation.